Table 1 Inclusion and exclusion criteria of the study
Inclusion criteria | |
Patients may enter the trial if all of the following apply: | |
1. Non-small-cell lung cancer is suspected | |
2. Radiologically diagnosed invasive lung tumor (a consolidation diameter > 5 mm or a whole lesion diameter > 30 mm is visualized by thin-section computed tomography) | |
3. Complete lobectomy planned | |
4. Complete resection including mediastinal lymph node dissection is planned | |
5. No synchronous or metachronous (within five years) malignancies, except for carcinoma in situ or mucosal tumors curatively treated with local therapy | |
6. Age ≥ 20 years | |
7. Eastern Cooperative Oncology Group performance status 0–1 | |
8. Sufficient organ function (leukocyte count ≥ 1500/mL, platelet count ≥ 100,000/mL, hemoglobin ≥ 8.0 g/dL, total bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase ≤ 100 IU/L, alanine aminotransferase ≤ 100 IU/L, peripheral arterial oxygen saturation on room air ≥ 92%) | |
9. Written informed consent from the patient | |
Exclusion criteria | |
Patients may not enter the trial if any of the following apply: | |
1. Active concurrent malignant diseases | |
2. Mental disorders that may affect the ability or willingness to provide informed consent or abide by the study protocol | |
3. Beta blocker medication necessary | |
4. Beta-2 stimulator medication necessary | |
5. Preoperative chemotherapy and/or radiotherapy to the target lesion | |
6. Systemic steroids or immunosuppressive agent medication | |
7. Uncontrollable infectious disease except for viral hepatitis | |
8. Serious complications (congestive heart failure, serious coronary insufficiency, acute myocardial infarction, renal failure, liver failure, hemorrhagic gastric ulcer, intestinal paralysis, intestinal obstruction, uncontrollable diabetes mellitus, etc.) | |
9. Uncontrollable autoimmune disease | |
10. Contraindicated for the test drug | |
- cardiogenic shock | |
- diabetic ketoacidosis or metabolic acidosis | |
- bradycardia including atrioventricular block and sick sinus syndrome | |
- right cardiac failure due to pulmonary hypertension | |
- untreated pheochromocytoma | |
- history of hypersensitivity to the test drug | |
11. Pregnant, lactating, or potentially pregnant | |
12. Participating in another clinical trial at time of enrolment | |
13. Deemed unsuitable by the primary investigator for other reasons |